Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081541 | 1.00 | DPP4 (0.57) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4077281 | 1.00 | DPP4 (0.57) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4074092 | 1.00 | DPP4 (0.57) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4076580 | 1.00 | DPP4 (0.57) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4074086 | 1.00 | DPP4 (0.57) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4087538 | 0.85 | F2 (0.49) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4082879 | 0.85 | F2 (0.49) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4082868 | 0.85 | F2 (0.49) | DPP4F2F10PRSS1GAA | |
| SCHEMBL4073916 | 0.78 | DPP4 (0.51) | DPP4GAACTSK | |
| SCHEMBL4076662 | 0.78 | DPP4 (0.51) | DPP4GAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | DPP4 987/4885F2 52/4885F10 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.